Filana Therapeutics
FLNA
174 hedge funds and large institutions have $439M invested in Filana Therapeutics in 2022 Q3 according to their latest regulatory filings, with 49 funds opening new positions, 43 increasing their positions, 34 reducing their positions, and 24 closing their positions.
104% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 24
60% more call options, than puts
Call options by funds: $276M | Put options by funds: $173M
57% more capital invested
Capital invested by funds: $279M → $439M (+$160M)
26% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 34
17% more funds holding
Funds holding: 149 → 174 (+25)
1.33% more ownership
Funds ownership: 24.89% → 26.21% (+1.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$6.49M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$4.25M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$3.34M |
| 4 |
GC
GMT Capital
Atlanta,
Georgia
|
+$3.11M |
| 5 |
SC
Sculptor Capital
New York
|
+$2.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$4.75M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
-$2.49M |
| 3 |
Stifel Financial
St. Louis,
Missouri
|
-$2.45M |
| 4 |
SG Americas Securities
New York
|
-$1.25M |
| 5 |
KAS
Kestra Advisory Services
Austin,
Texas
|
-$984K |
FLNA Hedge Fund Activity: Q3 2022 in Review
174 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Filana Therapeutics (FLNA) for Q3 2022, worth a combined $439M — up 57% from $279M a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new FLNA positions and 24 closed out — a net gain of 25 holders — while 43 added to existing stakes and 34 trimmed.
The largest buyer was Invesco, adding an estimated $6.49M. The largest seller was BlackRock, cutting an estimated $4.75M.
- 174 institutional investors held Filana Therapeutics (FLNA) as of Q3 2022, up from 149 in Q2 2022.
- Funds reported $439M of Filana Therapeutics stock for Q3 2022, up 57% quarter-over-quarter.
- 49 funds opened new Filana Therapeutics positions in Q3 2022 and 24 closed out, a net change of +25 holders.
- The largest Filana Therapeutics buyer in Q3 2022 was Invesco, an estimated $6.49M added.
- The largest Filana Therapeutics seller in Q3 2022 was BlackRock, an estimated $4.75M sold.
Based on aggregated 13F filings for Q3 2022.